home *** CD-ROM | disk | FTP | other *** search
- Path: sparky!uunet!europa.asd.contel.com!darwin.sura.net!zaphod.mps.ohio-state.edu!uwm.edu!rutgers!hsdndev!binoc.bih.harvard.edu!rind
- From: rind@binoc.bih.harvard.edu (David Rind)
- Newsgroups: sci.med
- Subject: Re: Aids, Inc. (was: RFD Alternative Medicine)
- Message-ID: <2181@hsdndev.UUCP>
- Date: 23 Nov 92 21:01:34 GMT
- References: <1992Nov16.205552.6554@island.COM> <17501@pitt.UUCP> <1992Nov23.165400.1204@island.COM>
- Sender: usenet@hsdndev.UUCP
- Organization: Beth Israel Hospital, Harvard Medical School, Boston Mass., USA
- Lines: 47
-
- In article <1992Nov23.165400.1204@island.COM> green@island.COM
- (Robert Greenstein) writes:
- >I just finished reading a most interesting interview with Jon Rappaport,
- >author of "AIDS, INC". I have not yet read the book, but the interview
- >raises some disturbing issues. He argues that AZT is a poison which
- >attacks the bone marrow, among other things.
-
- Wow, how did he ever break that story. I thought we allopaths were
- doing such a good job of covering it up. Do you think he found it
- in that secret book, the PDR which under the Warnings section for
- AZT has in the required bold face in a box format "therapy with
- [AZT] may be associated with hematologic toxicity including
- granulocytopenia and severe anemia requiring transfusions"?
-
- >the FDA, which licensed the drug in 1987 was aware of the danger. About
- >20% of the people in the licensing trial had to have multiple red-cell
- >transfusions because their blood was so badly damaged.
-
- Boy, the FDA sure seems to have been trying hard to hide this fact.
-
- >Rappaport says that information on the licensing trials obtained through
- >the Freedom of Information Act showed that the licensing trial was a
- >fraud. The trial became unblinded. People were comparing polls to see
- >who was taking the placebo and who was taking AZT. They began sharing AZT.
-
- Wow, he used the Freedom of Information Act!! Do you think he might
- have read the editorials and letters in various journals discussing
- the problems with maintaining blinding in AZT trials?
-
- By the way, if patients were crossing over from placebo to AZT without
- the investigators knowledge, do you think that biases the study toward
- the alternative hypothesis or to the null hypothesis?
-
- >In this interview Rappaport also talked about similar licensing scams
- >for neuroleptic drugs. They cause a form of brain damage known as
- >tardive dyskinesia. There are an estimated 38 million cases of
- >tardive dyskinesia globally, all caused by drugs licensed by the FDA.
-
- Well, while I'm quoting from the PDR without permission, how about
- from the first line of the Warnings section for Haldol (the first
- neuroleptic I thought of to check): "TARDIVE DYSKINESIA A syndrome
- consisting of..." I think you get the idea. These "licensing
- scams" sure are gonna fall apart if people get hold of that secret
- PDR book.
- --
- David Rind
- rind@binoc.bih.harvard.edu
-